Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

6
Zero-Sales Biotechs May Damage Your Financial Health - Bloomberg

2018-08-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK PFZ GSC TFG PFIZER GSJ RHHBF GS GLSSP RHHVF RHHBY BGNE GJS 500680 PFE

1
ICU Medical Drops After Report Smiths May Walk From Deal Talks - Bloomberg

2018-08-07 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ SMIN SMGZY SMGKF ICUI BAX 500680 PFE PFIZER

1
Pfizer: The Outlook Cannot Justify Current Valuation

2018-08-07 seekingalpha
Pfizer is currently trading at a ~20% discount rate, when taking into account discounted cash flows as well as a multiples analysis.
PFZ 500680 PFE PFIZER

73
Tracking Kahn Brothers Portfolio - Q2 2018 Update

2018-08-07 seekingalpha - 3
New York Community Bancorp stake was increased while reducing New York Times Company position significantly during the quarter.
XOM VOXX GNE SEB GSK SBT ZDGE BAC IDT IDT PFIZER BBRY CGBBW RFL NVS STL BB PFE BAC PVBC IDT.WI AGO RFL.WI BMY HOLX MBI PFZ BMYMP C CMCSA NYTAB BB GSK PTEN NAVI CVX NYCB NTP 500680

26
Disney, DowDuPont Set Pace for the Dow Monday

2018-08-06 247wallst
August 6, 2018: Markets opened slightly lower Monday and all three major indexes are on track to close in the green, although narrowly in the case of the Dow. Corporate earnings remain strong (those tax cuts are doing their intended job) but the continuing tariff battles are taking a toll on investor optimism. The telecom sector is posting Monday’s biggest gain while real-estate is the only loser for the day.
PFZ CSCO 500680 PFE PFIZER DWDP DIS

19
Antares Pharma Enters Into Development Agreement With Pfizer Inc.

2018-08-06 globenewswire
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a combination drug device rescue pen. This rescue pen will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. Pfizer will pay for the development of the product and will be responsible for obtaining FDA approval of the combination product.
ATRS AMAG PFZ TEVJF TEVA TEVVF 500680 PFE PFIZER

155
10 Hot Stocks to Invest In Right Now

2018-08-03 investorplace - 1
It’s a different market than it was at the beginning of 2018. Volatility has returned, even if it remains modest relative to historical levels. Big names like Procter & Gamble (NYSE:PG) and Walmart (NYSE:WMT), among others, have seen precipitous share price declines after record highs. What’s more, we’ve seen the first trillion-dollar company in Apple (NASDAQ:AAPL)
NTRI YUM XOM WMT AMZN AEO CMCSK UPS MPX WTW MCFT PFIZER BP NATH BRBW CGBBW ROKU NVS MBUU PFE BC VMI PG CCV CCZ LB BAC CHTR AAPL PFZ C CMCSA FDX T JPM CCV.CL CVX TSLA 500680 DPZ

4
IBM, Pfizer Lift the Dow Friday

2018-08-03 247wallst
August 3, 2018: Markets opened higher Friday but the Nasdaq Composite struggled all day to stay positive. It might just hold on by the closing bell. The report on non-farm payrolls came in weaker than expected but that may be okay. Trade issues continue to bedevil investors as corporate profits remain strong. Consumer staples is today’s strongest sector and energy the weakest.
IBM PFZ KO 500680 PFE PFIZER WMT

1
US tax cuts prompt rethink by some 'inverted' companies - Channel NewsAsia

2018-08-03 channelnewsasia
A few U.S. companies that moved offshore in a wave of inversion deals are considering returning to the United States now that domestic tax rates are lower and tax policing is tougher abroad, attorneys and consultants said.
PFZ 500680 PFE PFIZER MDT

1
U.S. tax cuts prompt rethink by some 'inverted' companies

2018-08-03 reuters
WASHINGTON (Reuters) - A few U.S. companies that moved offshore in a wave of inversion deals are considering returning to the United States now that domestic tax rates are lower and tax policing is tougher abroad, attorneys and consultants said.
PFZ 500680 PFE PFIZER MDT

2
IRS Blocks Refund for Companies Overpaying Offshore Profits Tax - Bloomberg

2018-08-03 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ AAPL 500680 PFE PFIZER

2
OPKO Health Completes Enrollment in Global Phase 3 Study of Somatrogon (hGH-CTP) in Growth Hormone Deficient Children

2018-08-03 globenewswire - 1
MIAMI, Aug. 03, 2018 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) has completed enrollment in the Company’s global pivotal Phase 3 study in growth hormone deficient children, evaluating a single weekly injection of its investigational long-acting human growth hormone product, somatrogon, delivered in a multi-dose disposable pen.
PFZ OPK 500680 PFE PFIZER

1
BioMarin Pharmaceutical (BMRN) Q2 2018 Results - Earnings Call Transcript

2018-08-03 seekingalpha
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Tracy.
PFZ MS 500680 PFE PFIZER BMRN

7
Allergan Sues Pfizer Over Damages in Opioid Litigation - Bloomberg

2018-08-02 bloomberg - 1
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ AGN MCK ACT 500680 PFE PFIZER

5
DNA Protection Pledges Fail to Address Main Concerns on Data Use - Bloomberg

2018-08-02 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
PFZ GSK 500680 PFE GSK PFIZER

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...